POST Online Media Lite Edition



 

Roche Group sales increased 4% to CHF 12.4 billion

Staff writer |
In the first quarter of 2016, Roche Group sales rose 4% to CHF 12.4 billion. Strong growth was recorded for the immunodiagnostic, molecular and tissue diagnostics businesses.

Article continues below






Sales in the Pharmaceuticals Division were up 4% to CHF 9.8 billion with Europe growing 5%, driven by Perjeta, MabThera and RoActemra. Pharmaceuticals sales in the US increased 3%, led by Esbriet, Xolair and HER2-positive breast cancer medicines.

The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer have had a good start. In the U.S., sales of Tamiflu and Lucentis declined.

The main growth contributors in the International region (+4%) were Avastin, MabThera and Herceptin; this growth was partly offset by lower Pegasys sales due to competition from a new generation of treatments. In Japan, sales rose 4% driven by Avastin, HER2 medicines and Alecensa.

In Diagnostics, sales grew 5% to CHF 2.6 billion, driven primarily by strong growth in Asia-Pacific (+16%) and Latin America (+21%).

In Europe, the Middle East, and Africa (EMEA) sales increased 1% while they remained stable in North America and declined by 3% in Japan.

Strong growth was recorded for the immunodiagnostic, molecular and tissue diagnostics businesses. Diabetes Care sales were impacted by challenging market conditions, especially in North America.


What to read next

Roche 2016 net income increased 7 percent
Roche sales increased 5% to CHF 48.1 billion
Roche group sales increased 6%